MDT
96.75
+0.6%↑
A
137.45
-0.45%↓
VEEV
225.06
+0.13%↑
HQY
92.81
+0.08%↑
PHR.US
16.98
+0.53%↑
MDT
96.75
+0.6%↑
A
137.45
-0.45%↓
VEEV
225.06
+0.13%↑
HQY
92.81
+0.08%↑
PHR.US
16.98
+0.53%↑
MDT
96.75
+0.6%↑
A
137.45
-0.45%↓
VEEV
225.06
+0.13%↑
HQY
92.81
+0.08%↑
PHR.US
16.98
+0.53%↑
MDT
96.75
+0.6%↑
A
137.45
-0.45%↓
VEEV
225.06
+0.13%↑
HQY
92.81
+0.08%↑
PHR.US
16.98
+0.53%↑
MDT
96.75
+0.6%↑
A
137.45
-0.45%↓
VEEV
225.06
+0.13%↑
HQY
92.81
+0.08%↑
PHR.US
16.98
+0.53%↑
24h
Šī brīža
Min
97.95
Max
101.75
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +74.68% upside |
By Acuity
58%
42%
317 / 374 Rangs Healthcare
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
2025. g. 29. dec. 22:03 UTC
Mining Stocks Slip Near the End of Stellar Year
DJ
Lasīt
2025. g. 29. dec. 15:57 UTC
Praxis Shares Rise on Ulixacaltamide Breakthrough Designation
DJ
Lasīt
2025. g. 29. dec. 23:43 UTC
Nikkei May Decline; Yen in Focus -- Market Talk
DJ
Lasīt
2025. g. 29. dec. 23:38 UTC
Manus: Will Continue to Operate From Singapore
DJ
Lasīt
2025. g. 29. dec. 23:38 UTC
Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website
DJ
Lasīt
2025. g. 29. dec. 23:37 UTC
Meta Platforms: Will Integrate Manus Service Into Products
DJ
Lasīt
2025. g. 29. dec. 23:36 UTC
Meta Platforms: Will Continue to Operate, Sell Manus Service
DJ
Lasīt
2025. g. 29. dec. 23:36 UTC
Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products
DJ
Lasīt
2025. g. 29. dec. 23:35 UTC
Manus to Join Meta Platforms
DJ
Lasīt
2025. g. 29. dec. 21:33 UTC
Origin: Raise Values Kraken at US$8.65 Billion
DJ
Lasīt
2025. g. 29. dec. 21:33 UTC
Origin: Octopus Targeting Kraken Separation by Mid 2026
DJ
Lasīt
2025. g. 29. dec. 21:31 UTC
BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses
DJ
Lasīt
2025. g. 29. dec. 21:31 UTC
BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose
DJ
Lasīt
2025. g. 29. dec. 21:30 UTC
Origin's Kraken Stake to Remain at 22.7%
DJ
Lasīt
2025. g. 29. dec. 21:30 UTC
Origin Will Continue to Hold Its 22.7% Interest in Octopus
DJ
Lasīt
2025. g. 29. dec. 21:30 UTC
BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months
DJ
Lasīt
2025. g. 29. dec. 21:30 UTC
Origin: Additional Interest Offsets Dilution From Raise
DJ
Lasīt
2025. g. 29. dec. 21:30 UTC
BlueScope Doesn't Expect Material Impact on 1H Guidance Range
DJ
Lasīt
2025. g. 29. dec. 21:29 UTC
Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest
DJ
Lasīt
2025. g. 29. dec. 21:29 UTC
BlueScope Expects to Complete Property Sale for A$76 Million Consideration
DJ
Lasīt
2025. g. 29. dec. 21:29 UTC
BlueScope Expects to Complete Property Sale in 2H of FY 2026
DJ
Lasīt
2025. g. 29. dec. 21:28 UTC
BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder
DJ
Lasīt
2025. g. 29. dec. 21:28 UTC
Origin: Kraken's Raise Paves Way for Separation From Octopus Energy
DJ
Lasīt
2025. g. 29. dec. 21:28 UTC
Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors
DJ
Lasīt
2025. g. 29. dec. 21:28 UTC
BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto
DJ
Lasīt
2025. g. 29. dec. 21:27 UTC
Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise
DJ
Lasīt
2025. g. 29. dec. 20:22 UTC
Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk
DJ
Lasīt
2025. g. 29. dec. 20:14 UTC
U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk
DJ
Lasīt
2025. g. 29. dec. 20:02 UTC
Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com
DJ
Lasīt
2025. g. 29. dec. 17:36 UTC
U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk
DJ
Lasīt
Cenas izmaiņa
By TipRanks
Prognoze 12 mēnešiem
Vidējais 180.57 USD 74.68%
Augstākais 212 USD
Zemākais 133 USD
Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Palvella Therapeutics Inc — pēdējo 3 mēnešu laikā.
By TipRanks
Pirkt (spēcīgs)
14 ratings
14
Pirkt
0
Turēt
0
Pārdot
Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Palvella Therapeutics Inc — pēdējo 3 mēnešu laikā.
By Acuity
Ziņu noskaņojums
Liecība "Lāču" tendencei
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Virs vidējā
$